How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care

Research output: Contribution to journalArticlepeer-review


​​​​​​ Clinicians now have 2 effective and well-tolerated vesicular monoamine transporter 2 (VMAT2) inhibitors-valbenazine and deutetrabenazine-for the treatment of patients with tardive dyskinesia (TD), a severe and potentially irreversible side effect associated with dopamine receptor blocking agents. Clinicians should use measurement-based care, eg, the Abnormal Involuntary Movement Scale with activation maneuvers, to assess and document TD symptoms and treatment progress. Each follow-up visit should be personalized with questions related to patients' functioning and level of distress regarding their specific TD symptoms. Family members, if available, can provide information on symptom changes and assistance with medication adherence. With continued treatment and measurement-based care, patients can experience improvement in their TD symptoms.

Original languageEnglish (US)
JournalThe Journal of clinical psychiatry
Issue number6
StatePublished - Nov 3 2020

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care'. Together they form a unique fingerprint.

Cite this